IRLAB Therapeutics AB
STO:IRLAB A

Watchlist Manager

IRLAB Therapeutics AB

STO:IRLAB A

Watchlist

Dividends

Price: 12.6 SEK -1.95% Market Closed

Market Cap: 652.5m SEK

Have any thoughts about
IRLAB Therapeutics AB?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Fubotv Inc NYSE:FUBO	Media
US	Bank of America Corp NYSE:BAC	Banking
US	Palantir Technologies Inc NYSE:PLTR	Technology
US	Uber Technologies Inc NYSE:UBER	Road & Rail
CN	NIO Inc NYSE:NIO	Automobiles
US	Fluor Corp NYSE:FLR	Construction
US	Jacobs Engineering Group Inc NYSE:J	Professional Services
US	TopBuild Corp NYSE:BLD	Consumer products
US	Abbott Laboratories NYSE:ABT	Health Care
US	Chevron Corp NYSE:CVX	Energy
US	Occidental Petroleum Corp NYSE:OXY	Energy
US	Matrix Service Co NASDAQ:MTRX	Construction
US	Automatic Data Processing Inc NASDAQ:ADP	Technology
US	Qualcomm Inc NASDAQ:QCOM	Semiconductors
US	PayPal Holdings Inc NASDAQ:PYPL	Technology
US	Ambarella Inc NASDAQ:AMBA	Semiconductors

Add Price Alert

Price Target:

Last Price: 12.6 SEK

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

IRLAB A Alert

IRLAB Therapeutics AB

12.6

-0.25 (-1.95%)

52 Week Range	5.9 19.6
Price Target

We'll email you a reminder when the closing price reaches SEK.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Fubotv Inc NYSE:FUBO	US
	Bank of America Corp NYSE:BAC	US
	Palantir Technologies Inc NYSE:PLTR	US
	Uber Technologies Inc NYSE:UBER	US
	NIO Inc NYSE:NIO	CN
	Fluor Corp NYSE:FLR	US
	Jacobs Engineering Group Inc NYSE:J	US
	TopBuild Corp NYSE:BLD	US
	Abbott Laboratories NYSE:ABT	US
	Chevron Corp NYSE:CVX	US
	Occidental Petroleum Corp NYSE:OXY	US
	Matrix Service Co NASDAQ:MTRX	US
	Automatic Data Processing Inc NASDAQ:ADP	US
	Qualcomm Inc NASDAQ:QCOM	US
	PayPal Holdings Inc NASDAQ:PYPL	US
	Ambarella Inc NASDAQ:AMBA	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

IRLAB Therapeutics AB

What unique competitive advantages
does IRLAB Therapeutics AB hold over its rivals?

What risks and challenges
does IRLAB Therapeutics AB face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of IRLAB Therapeutics AB.

What unique competitive advantages
does IRLAB Therapeutics AB hold over its rivals?

What risks and challenges
does IRLAB Therapeutics AB face in the near future?

Has there been any significant insider trading activity
in IRLAB Therapeutics AB recently?

Summarize the latest earnings call
of IRLAB Therapeutics AB.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for IRLAB Therapeutics AB.

Provide P/S
for IRLAB Therapeutics AB.

Provide P/E
for IRLAB Therapeutics AB.

Provide P/OCF
for IRLAB Therapeutics AB.

Provide P/FCFE
for IRLAB Therapeutics AB.

Provide P/B
for IRLAB Therapeutics AB.

Provide EV/S
for IRLAB Therapeutics AB.

Provide EV/GP
for IRLAB Therapeutics AB.

Provide EV/EBITDA
for IRLAB Therapeutics AB.

Provide EV/EBIT
for IRLAB Therapeutics AB.

Provide EV/OCF
for IRLAB Therapeutics AB.

Provide EV/FCFF
for IRLAB Therapeutics AB.

Provide EV/IC
for IRLAB Therapeutics AB.

Show me price targets
for IRLAB Therapeutics AB made by professional analysts.

What are the Revenue projections
for IRLAB Therapeutics AB?

How accurate were the past Revenue estimates
for IRLAB Therapeutics AB?

What are the Net Income projections
for IRLAB Therapeutics AB?

How accurate were the past Net Income estimates
for IRLAB Therapeutics AB?

What are the EPS projections
for IRLAB Therapeutics AB?

How accurate were the past EPS estimates
for IRLAB Therapeutics AB?

What are the EBIT projections
for IRLAB Therapeutics AB?

How accurate were the past EBIT estimates
for IRLAB Therapeutics AB?

Compare the revenue forecasts
for IRLAB Therapeutics AB with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of IRLAB Therapeutics AB and its key competitors using the latest financial data.

Compare historical revenue growth rates
of IRLAB Therapeutics AB against its competitors.

Analyze the profit margins
(gross, operating, and net) of IRLAB Therapeutics AB compared to its peers.

Compare the P/E ratios
of IRLAB Therapeutics AB against its peers.

Discuss the investment returns and shareholder value creation
comparing IRLAB Therapeutics AB with its peers.

Analyze the financial leverage
of IRLAB Therapeutics AB compared to its main competitors.

Show all profitability ratios
for IRLAB Therapeutics AB.

Provide ROE
for IRLAB Therapeutics AB.

Provide ROA
for IRLAB Therapeutics AB.

Provide ROIC
for IRLAB Therapeutics AB.

Provide ROCE
for IRLAB Therapeutics AB.

Provide Gross Margin
for IRLAB Therapeutics AB.

Provide Operating Margin
for IRLAB Therapeutics AB.

Provide Net Margin
for IRLAB Therapeutics AB.

Provide FCF Margin
for IRLAB Therapeutics AB.

Show all solvency ratios
for IRLAB Therapeutics AB.

Provide D/E Ratio
for IRLAB Therapeutics AB.

Provide D/A Ratio
for IRLAB Therapeutics AB.

Provide Interest Coverage Ratio
for IRLAB Therapeutics AB.

Provide Altman Z-Score Ratio
for IRLAB Therapeutics AB.

Provide Quick Ratio
for IRLAB Therapeutics AB.

Provide Current Ratio
for IRLAB Therapeutics AB.

Provide Cash Ratio
for IRLAB Therapeutics AB.

What is the historical Revenue growth
over the last 5 years for IRLAB Therapeutics AB?

What is the historical Net Income growth
over the last 5 years for IRLAB Therapeutics AB?

What is the current Free Cash Flow
of IRLAB Therapeutics AB?

Discuss the annual earnings per share (EPS)
trend over the past five years for IRLAB Therapeutics AB.

IRLAB A

Cash Flow Statement

Cash from Financing Activities

IRLAB Therapeutics AB
Cash from Financing Activities

Last Value

3-Years 3-Y CAGR

5-Years 5-Y CAGR

10-Years 10-Y CAGR

Quarterly

Annual

TTM

Adjust for Inflation

IRLAB Therapeutics AB
Cash from Financing Activities Peer Comparison

Comparables:

CALTX

CAMX

SECARE

MOB

FLERIE

Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors

Company		Cash from Financing Activities	CAGR 3Y	CAGR 5Y	CAGR 10Y
	IRLAB Therapeutics AB STO:IRLAB A	Cash from Financing Activities kr23.7m	CAGR 3-Years -55%	CAGR 5-Years -29%	CAGR 10-Years N/A
	Calliditas Therapeutics AB STO:CALTX	Cash from Financing Activities kr196.1m	CAGR 3-Years N/A	CAGR 5-Years -22%	CAGR 10-Years N/A
	Camurus AB STO:CAMX	Cash from Financing Activities kr1.3B	CAGR 3-Years 45%	CAGR 5-Years 22%	CAGR 10-Years N/A
S	Swedencare AB (publ) STO:SECARE	Cash from Financing Activities -kr298.5m	CAGR 3-Years N/A	CAGR 5-Years -99%	CAGR 10-Years N/A
	Moberg Pharma AB (publ) STO:MOB	Cash from Financing Activities kr92.3m	CAGR 3-Years N/A	CAGR 5-Years N/A	CAGR 10-Years N/A
I	InDex Pharmaceuticals Holding AB STO:FLERIE	Cash from Financing Activities kr572.3m	CAGR 3-Years 6%	CAGR 5-Years 74%	CAGR 10-Years N/A

What is IRLAB Therapeutics AB's Cash from Financing Activities?

Cash from Financing Activities
23.7m SEK

Based on the financial report for Dec 31, 2023, IRLAB Therapeutics AB's Cash from Financing Activities amounts to 23.7m SEK.

What is IRLAB Therapeutics AB's Cash from Financing Activities growth rate?

Cash from Financing Activities CAGR 5Y
-29%

The average annual Cash from Financing Activities growth rates for IRLAB Therapeutics AB have been -55% over the past three years , -29% over the past five years .

IRLAB Therapeutics AB
STO:IRLAB A

IRLAB Therapeutics AB
Cash from Financing Activities

IRLAB Therapeutics AB
Cash from Financing Activities Peer Comparison

Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors

See Also

What is IRLAB Therapeutics AB's Cash from Financing Activities?

Cash from Financing Activities
23.7m SEK

What is IRLAB Therapeutics AB's Cash from Financing Activities growth rate?

Cash from Financing Activities CAGR 5Y
-29%

Company

Help

Tools

Stocks

IRLAB Therapeutics AB STO:IRLAB A

IRLAB Therapeutics AB Cash from Financing Activities

IRLAB Therapeutics AB Cash from Financing Activities Peer Comparison

Competitive Cash from Financing Activities Analysis Latest Figures & CAGR of Competitors

See Also

What is IRLAB Therapeutics AB's Cash from Financing Activities? Cash from Financing Activities 23.7m SEK

What is IRLAB Therapeutics AB's Cash from Financing Activities growth rate? Cash from Financing Activities CAGR 5Y -29%

Company

Help

Tools

Stocks

IRLAB Therapeutics AB
STO:IRLAB A

IRLAB Therapeutics AB
Cash from Financing Activities

IRLAB Therapeutics AB
Cash from Financing Activities Peer Comparison

Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors

What is IRLAB Therapeutics AB's Cash from Financing Activities?

Cash from Financing Activities
23.7m SEK

What is IRLAB Therapeutics AB's Cash from Financing Activities growth rate?

Cash from Financing Activities CAGR 5Y
-29%